key: cord-0970849-h0qiyfn1 authors: Morgado-Carrasco, D.; Ibaceta-Ayala, J.; Piquero-Casals, J. title: [Translated article] Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19 date: 2022-02-28 journal: Actas Dermo-Sifiliográficas DOI: 10.1016/j.ad.2022.01.012 sha: 05b83cd591984fcd98d94416b4f34948d02934ea doc_id: 970849 cord_uid: h0qiyfn1 Hydroxychloroquine is an antimalarial drug with immunomodulatory, anti-inflammatory, antibacterial, and antiviral properties. It has a good safety profile, can be used in children and in pregnant and breastfeeding women, and does not suppress the immune system. Regular screening for retinopathy, one of the drug’s most feared adverse effects, is necessary. Hydroxychloroquine is a widely used, essential drug in dermatology. Clinical response rates are good in lupus erythematous, where it is a first-line therapy, as well in numerous autoimmune/inflammatory diseases, including lichen planus, polymorphic light eruption, porphyria cutanea tarda, granuloma annulare, and sarcoidosis. In 2020, it was widely prescribed both to prevent and to treat COVID-19 caused by SARS-CoV-2. Its increased use led to serious supply shortages and in some cases stocks were entirely depleted. Recent meta-analyses have concluded that hydroxychloroquine is ineffective against COVID-19 and have advised against its use. Hydroxychloroquine is an antimalarial drug derived from chloroquine. It is inexpensive and has a favorable safety profile 1 . Hydroxychloroquine has immunomodulatory, antiinflammatory, and photoprotective properties, although it can act as a photosensitizer. In dermatology, it is a firstline agent for the treatment of lupus erythematosus and is widely used off-label in multiple autoimmune and inflammatory skin diseases ( Fig. 1 ) 1---3 . Its antibacterial, antifungal, and antiviral properties led it to be prescribed off-label for the prophylaxis and treatment of SARS-CoV-2 infection (COVID-19) 4, 5 . The increased use of hydroxychloroquine in this setting led to difficulties obtaining the drug and even temporary depletion of stocks. The present review examines the use of hydroxychloroquine in dermatology, its mechanism of action and toxicities, and the threat that COVID-19 constituted for the supply of the drug. Hydroxychloroquine has high oral bioavailability, with 45% eliminated via the kidneys 3 . It is metabolized by cytochrome P450, although its plasma levels are not affected by inducers or inhibitors of this enzyme 2 ( Table 1) . The mechanism of action of hydroxychloroquine is complex. Its immunomodulatory effect stems from the inhibition of antigen presentation via the major histocompatibility complex, stabilization of lysosomal membranes, reduced cell-mediated cytotoxicity, and inhibition of multiple intracellular toll-like receptors 3 . Its anti-inflammatory effect is secondary to inhibition of phospholipase A2 and C and of various cytokines (tumor necrosis factor ␣, interferon ␣ and ␥, and interleukin [IL] 1, 2, and 6) 2 , and its photoprotective effect is secondary to its antioxidant and DNA-stabilizing properties, as well as to reduced levels of interleukins after UV radiation (Table 2) 3 . Hydroxychloroquine also diminishes survival of viruses, bacteria, and fungi in lysosomes and endosomes 3 . Hydroxychloroquine is approved by the United States Food and Drug Administration and the European Medicines Agency for the treatment of lupus erythematosus. Hydroxychloroquine has a favorable safety profile and is rarely discontinued owing to adverse effects. Retinal toxicity, one of the most feared effects, has been observed in 7.5% of patients, although it is extremely rare during the first 5 years of treatment. Doses greater than 5 mg/kg/d for more than 10 years are associated with an increased rate of retinopathy (Table 3) 6 . Gastrointestinal adverse effects are relatively common and include anorexia, heartburn, diarrhea, and abdominal distension 3 . The most common cutaneous adverse effects are rash, hyperpigmentation, and pruritis, as well as photosensitivity. Other, uncommon adverse effects include cardiac, muscular, and hematologic conditions 7 (Table 4 ). An ophthalmological examination should be performed at baseline and annually after 5 years of therapy. A recent review did not report hemolysis during therapy with hydroxychloroquine in patients with a deficiency of the enzyme glucose-6-phosphate dehydrogenase; therefore, its routine assessment is not recommended 7 . Table 5 shows the main recommendations. Antimalarial drugs are first-line agents for the treatment of systemic lupus erythematosus (SLE). They reduce joint and skin symptoms, disease activity, target organ damage, and cardiovascular complications and increase survival 8 . As for cutaneous lupus erythematosus (CLE), a recent systematic review of 10 studies and 852 patients revealed an effectiveness of 50% to 79% (50% in the 2 randomized clinical trials included) 9 ( Table 6 ). The degree of efficacy varied depending on the subtype of CLE and was greater for acute CLE than for subacute CLE and chronic CLE 10 . In the case of tumid lupus erythematosus, a retrospective study (n = 36) revealed satisfactory responses with hydroxychloroquine in 61% of cases 9 . Hydroxychloroquine seems to be effective in lupus panniculitis 2 . The time to clinical response is another factor that depends on the subtype of CLE; therefore, the effectiveness of hydroxychloroquine should be evaluated at 4 weeks in acute disease, 5 weeks in subacute disease, and 8 weeks in chronic disease 10 . Various alternatives can be used for CLE that fails to respond to hydroxychloroquine. These include determining plasma levels of hydroxychloroquine. In SLE, therapeutic levels are between 500 and 1000 ng/mL. The optimal ranges for CLE have not yet been determined. Values lower than 200 ng/mL are associated with poor adherence. In refractory cases, increasing the dose to concentrations higher than 750 ng/mL has been associated with a significant improvement in symptoms 1 . Another option involves switching to chloroquine, which improves the skin condition in a significant percentage of patients, albeit with a poorer safety profile. Hydroxychloroquine can also be combined with quinacrine 100 mg/d 2,3 . This agent is not sold in Spain and must be obtained as a foreign medication. Treatment of the cutaneous manifestations of dermatomyositis can prove more difficult than that of the muscular manifestations. A retrospective multicenter study of 115 persons (93 with amyopathic dermatomyositis and 22 with hypomyopathic dermatomyositis) showed that antimalarial agents were the most frequently indicated treatment (76%), with skin involvement controlled in only 11%. Most patients needed immunosuppressants or immunoglobulins 11 . Similar results were recorded in a cohort study of 41 persons with amyopathic dermatomyositis 12 . A recent study revealed a significant increase in interferon ␤---producing myeloid dendritic cells in the skin of patients with dermatomyositis who had not responded to treatment with hydroxychloroquine. The increase in this cell subtype could account for the diminished response to antimalarial drugs 13 . Some studies have reported that individuals with dermatomyositis may be more frequently affected by hydroxychloroquine-induced cutaneous adverse effects (around 10%) than patients with SLE 14 , although this has not been confirmed by other authors. A recent retrospective study (n = 84) reported a complete response rate that was greater than 40% and a partial response rate of around 50%. The median time to optimal clinical response was 12 months. Patients with plaque morphea responded better than those with generalized, linear, or deep forms 15 . Another retrospective study of 16 patients with eosinophilic fasciitis showed that 25% of patients who received hydroxychloroquine in monotherapy achieved a complete response and 50% a partial response. Hydroxychloroquine was a good alternative, although it was not superior to oral corticosteroids 16 . A retrospective multicenter study of 57 persons with hypocomplementemic urticarial vasculitis revealed that hydroxychloroquine was effective as a first-line treatment, with response rates similar to those of systemic corticosteroids and an overall response rate (complete + partial) of more than 50%, albeit with reduced efficacy in cases of recurrence and cases refractory to other drugs 17 . A recent systematic review on urticarial vasculitis concluded that hydroxychloroquine (400 mg/d) is potentially effective in this disease and enables corticosteroids to be tapered 18 . A retrospective study (n = 61) of patients with cutaneous lichen planus (54%), cutaneous and mucosal lichen planus (25%), or mucosal lichen planus (21%) revealed resolution of symptoms in 61% of patients treated with hydroxychloroquine 400 mg/d in a mean of 80 days 19 . Favorable responses have been reported in isolated cases of actinic lichen planus 20 . In a series of 21 patients with oral erosive lichen planus treated with hydroxychloroquine 400 mg/d for 2 to 4 months, a complete response was recorded in 24% and at least moderate improvement in 57% 21 . A previous openlabel clinical trial (n = 10) had found similar results. 22 In a prospective study (n = 8), a significant clinical improvement was recorded in all patients with antimalarial drugs (7 with chloroquine 3.5-6 mg/kg/d and 1 with hydroxychloroquine 400 mg/d) after a mean of 2.4 months 23 . A retrospective study of patients with lichen planus of the vulva and vagina (n = 15) revealed a clinical response rate of 60% with a dose of hydroxychloroquine 200-800 mg/d (400 mg/d in most patients); median time to response was 5 months 24 . A retrospective study of 23 patients with lichen planopilaris (n = 40) revealed a complete response with hydroxychloroquine in 61% of patients 25 . Another retrospective study reported diminished disease activity in 83% of cases after 12 months of treatment 26 . However, methotrexate proved superior to hydroxychloroquine for reducing disease activity in a randomized clinical trial (n = 29) 27 . b Assessment should include campimetry and optical coherence tomography. This can be performed at shorter intervals in high-risk patients (Table 3) . Ophthalmological screening does not prevent damage, but only makes it possible to detect retinopathy at early stages and thus prevent progression. Treatment should be discontinued if retinopathy is suspected. c No agreement on the need for regular checkups or on optimal intervals. Measurement of glucose-6-phosphate dehydrogenase levels is not necessary. A recent review of the literature reported stabilization of frontal fibrosing alopecia in 71% of cases (41/58). The authors recommended hydroxychloroquine as secondline therapy after combination therapy with intralesional corticosteroids and topical minoxidil and tacrolimus 28 . A retrospective study of 36 patients with frontal fibrosing alopecia treated with various drugs (16 with hydroxychloroquine) revealed a response rate of 73% for hydroxychloroquine, although most were partial responses (64%) 29 . Similar results were reported in another retrospective study that included 11 patients with frontal fibrosing alopecia 26 . A large-scale retrospective multicenter study revealed stabilization of disease with hydroxychloroquine in 59% of cases (32/54) and improvement of symptoms in 15% (8/54) 30 . A retrospective study of 9 children with refractory alopecia areata (7 with severe alopecia areata) revealed regrowth greater than 50% in 5 cases (2 patients reached an almost complete response after 1 year of therapy) 31 . However, no favorable responses were observed in a series of 8 adult patients 2 . A randomized clinical trial including 48 patients with H 1 antihistamine---refractory chronic spontaneous urticaria compared the combination of placebo and high doses of H 1 antihistamines (4 tablets per day) with the combination of hydroxychloroquine and high-dose H 1 antihistamines. In the hydroxychloroquine group, 28% achieved full remission compared with 0% in the control group (P = .01) 32 . Granuloma annulare A retrospective study of 18 patients, most of whom had generalized granuloma annulare showed that 55% improved with hydroxychloroquine 33 . Similar results were found in a prospective case series (n = 9) 34 . Favorable results have been reported in annular elastolytic giant-cell granuloma 2 . In a series of 8 patients treated with antimalarial agents (6 with chloroquine and 2 with hydroxychloroquine), an almost complete response was recorded in 4 patients and stabiliza-tion of symptoms in 3 35 . Favorable findings have also been reported in isolated cases of ulcerative forms 36 . An open-label clinical trial (n = 17) revealed that 71% of patients achieved a complete clinical response and 33% a partial response 37 . In a series of 3 cases, the lesions resolved in all 3 patients 38 . Complete remission with oral prednisone and hydroxychloroquine has also been reported with ulcerative cutaneous sarcoidosis 39 . Porphyria cutanea tarda A randomized clinical trial (n = 48) found that low-dose hydroxychloroquine (100 mg twice weekly) was as effec- 43 . Hydroxychloroquine is a safe and effective option in children with actinic prurigo at doses of 3-5 mg/kg (the dose can be reduced by half after a few months) 44 . A clinical trial analyzing 66 patients with rosacea compared the effectiveness of hydroxychloroquine 400 mg/d with that of doxycycline 100 mg/d for 2 months; similar results were reported for both groups. The authors concluded that hydroxychloroquine could be effective in this disease and, therefore, could be used for the treatment of rosacea in pregnant women, for whom few alternative treatments are available 45 . Favorable responses to hydroxychloroquine have been reported in the treatment of diseases such as lichen sclerosus, reticular erythematous mucinosis, lipodermatosclerosis, chronic ulcerative stomatitis, chronic actinic dermatitis, solar urticaria 2 , Schnitzler syndrome, scleromyxedema, eosinophilic annular erythema, antiphospholipid syndrome, Kikuchi-Fujimoto disease 1 , pseudolymphoma 3 , Jessner lymphocytic infiltration of the skin, pemphigus foliaceus, interstitial granulomatous dermatitis, follicular mucinosis, and chronic erythema nodosum 46 (Table 7) . As we have seen, hydroxychloroquine is a polyvalent drug. It can be prescribed in many skin conditions, with favorable clinical outcomes. Its immunomodulatory----but not immunosuppressive----action and favorable safety profile make it suitable even for children and pregnant and breastfeeding women 1 . Given that a satisfactory clinical response generally takes several months, patients should be forewarned in order to avoid discontinuation. Hydroxychloroquine has potent antifungal, antibacterial, and antiviral properties. An antiviral effect has been reported against a series of viruses, including influenza A and B, hepatitis B and C, herpes simplex, chikungunya, dengue, Zika, and Ebola. Hydroxychloroquine was considered one of the most promising drugs for the treatment of COVID-19. Its role as an antiviral agent is based on its potential ability to inhibit fusion of the virus with the host cell, block transport of the virus from the endosomes to the endolysosomes, and diminish the cytokine storm in severely ill patients 3 . Antimalarial drugs interfere with glycosylation of the angiotensin-converting enzyme receptor, which is used by SARS-CoV-2 to enter cells, thus reducing viral penetration. They also alkalinize endosomes and endocytic vesicles, thus altering endocytosis of the virus, and diminish release of proinflammatory cytokines by reducing antigen presentation (especially of self-antigens) and activation of CD4 + T lymphocytes. They also reduce intracellular signaling of toll-like receptors 47, 48 . Despite the absence of consistent evidence that hydroxychloroquine was effective for treatment or prevention of COVID-19 and the fact that the Infectious Diseases Society of America only recommended it within the setting of randomized clinical trials, this antimalarial agent was used in various hospital treatment protocols and even recommended to the general public 4 . The United States Food and Drug Administration warned about potential cardiovascular effects of the drug and then authorized it for use in patients hospitalized with COVID-19 (March 28, 2020). They subsequently withdrew this authorization (June 15, 2020) 49 . The high demand for the drug (which multiplied 80fold in the USA) led to difficulties with administration and shortages 5 . Furthermore, India, one of the main producers of generic hydroxychloroquine, temporarily banned exportation of the drug, thus affecting the global supply chain 4 . In an international survey sent to members of the Systemic Lupus International Collaborating Clinics (29% European), 55% reported a shortage of supplies of hydroxychloroquine for patients with SLE during the pandemic 50 . Other authors reported anxiety and uncertainty among patients with SLE who could not access the drug 8, 51 . Furthermore, a major impact on malaria control programs was observed 5, 52 . We were unable to find original articles on the impact of the shortage on patients with dermatologic conditions, although we believe that if this had continued over time, then the impact would have been considerable. As for the effectiveness of hydroxychloroquine in COVID-19, a recent meta-analysis of 14 studies (n = 12 455) found no significant differences in survival, improvement in symptoms at day 10, or seroconversion rate and reported a greater frequency of cardiovascular and gastrointestinal effects than in the control groups 49 . A recent Cochrane database review revealed no significant differences in the risk of death from COVID-19 (or in the need for mechanical ventilation) when hydroxychloroquine was prescribed, and the authors recommended not performing further randomized clinical trials with this drug for this disease 53 . Similarly, a recent randomized clinical trial (n = 2314) was unable to find a positive effect for hydroxychloroquine as prophylaxis in COVID-19 54 . Hydroxychloroquine is a key drug for control of malaria and treatment of patients with specific rheumatologic and/or dermatologic conditions. We feel that it is important to recommend caution when prescribing this drug off-label for other conditions (including COVID-19) in order to ensure supply to those patients who need it. Hydroxychloroquine is an essential element of the dermatologist's therapeutic arsenal. It is indicated as first-or second-line therapy in many photoinduced and photoaggravated inflammatory and granulomatous skin diseases. Using hydroxychloroquine for the treatment and prevention of COVID-19 has proven unsatisfactory and led to supply difficulties. Greater caution is required when recommending large-scale, off-label prescription of hydroxychloroquine to ensure that patients who need this drug have access to it. Updated recommendations on the use of hydroxychloroquine in dermatologic practice Hydroxychloroquine in dermatology: new perspectives on an old drug Hydroxychloroquine in dermatology and beyond: recent update To dispense or not to dispense: lessons to be learnt from ethical challenges faced by pharmacists in the COVID-19 pandemic Competing health risks associated with the COVID-19 pandemic and response: a scoping review The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-Deficient patients Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 pandemic An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers The systemic management of cutaneous dermatomyositis: results of a stepwise strategy Myeloid dendritic cells are major producers of interferon-␤ in dermatomyositis and may contribute to hydroxychloroquine refractoriness Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at Mayo Clinic, 1996-2013 Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients Treatment of urticarial vasculitis: a systematic review Successful systemic treatment outcomes of lichen planus: a single-center retrospective review Childhood actinic lichen planus: successful treatment with antimalarials Hydroxychloroquine sulphate therapy of erosive oral lichen planus Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial Antimalarial drugs for the treatment of oral erosive lichen planus The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina The role of hydroxychloroquine in the treatment of lichen planopilaris: a retrospective case series and review Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: a randomized clinical trial Medical therapy for frontal fibrosing alopecia: a review and clinical approach Frontal fibrosing alopecia: a clinical review of 36 patients Frontal fibrosing alopecia: a multicenter review of 355 patients Alopecia areata treated with hydroxychloroquine: a retrospective study of nine pediatric cases Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study Antimalarial therapy for granuloma annulare: Results of a retrospective analysis Treatment of generalized granuloma annulare with hydroxychloroquine Successful treatment of necrobiosis lipoidica with antimalarial agents Significant improvement in ulcerative necrobiosis lipoidica with hydroxychloroquine Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas Micropapular cutaneous sarcoidosis: case series successfully managed with hydroxychloroquine sulfate Ulcerative sarcoidosis: a prototypical presentation and review Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multicenter, randomized, double-blind, doubledummy, pilot study Hydroxychloroquine and chronic erythema nodosum Familiar dermatologic drugs as therapies for COVID-19 Treatment of COVID 19-Repurposing drugs commonly used in dermatology The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 ----a systematic review and metaanalysis Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in Africa: caution for inappropriate off-label use in healthcare settings Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19 The authors declare that they have no conflicts of interest.